Commission Implementing Regulation (EU) 2020/1821 of 2 December 2020 authorising the placing on the market of an extract from Panax notoginseng and Astragalus membranaceus as a novel food under Regulation (EU) 2015/2283 of the European Parliament and of the Council and amending Commission Implementing Regulation (EU) 2017/2470 (Text with EEA relevance)

| Article 1 | (1) Extract from Panax notoginseng and Astragalus membranaceus as specified |
|-----------|---|
| Article 2 | The data contained in the application file on the basis |
| Article 3 | The Annex to Implementing Regulation (EU) 2017/2470 is amended in |
| Article 4 | This Regulation shall enter into force on the twentieth day Signature |
| | |

ANNEX

The Annex to Implementing Regulation (EU) 2017/2470 is amended as...

in Table 1 (Authorised novel foods), the following entry is...

Changes to legislation: There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/1821. (See end of Document for details)

- (1) OJ L 327, 11.12.2015, p. 1.
- (2) Commission Implementing Regulation (EU) 2017/2470 of 20 December 2017 establishing the Union list of novel foods in accordance with Regulation (EU) 2015/2283 of the European Parliament and of the Council on novel foods (OJ L 351, 30.12.2017, p. 72).
- (3) Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements (OJ L 183, 12.7.2002, p. 51).
- (4) EFSA Journal 2020;18(5):6099.
- (5) Pasics Szakonyiné I, 2011 (unpublished study report). Repeated dose 28-day oral gavage toxicity study with AstraGinTM in rats. Study No: 413.407.3084. Toxi-Coop Zrt., Hungary.
- (6) Zin HM, 2016 (unpublished study report). Bacterial reverse mutation test (Ames test) for AstraGinTM. Study code: GLP/J165/2016/48). Environmental Technology Research Centre (ETRC). Shah Alam, Selangor, Malaysia.
- (7) Upadhyaya S and Wang R, 2017 (unpublished study report). 90-days repeated dose oral toxicity study of Astragin® in Wistar rats. 161101/NVS/PC. July 2017. 319pp. Vedic Life Sciences Pvt, Ltd. Mumbai, India.
- (8) Vedic Lifesciences, 2019a (unpublished study report). Panax notoginseng proprietary extract: in vitro micronucleus test in CHO-K1 cells. Study Nr. 190503/NL/PC. Mumbai, India.
- (9) Vedic Lifesciences, 2019b (unpublished study report). Astragalus membranaceus extract: in vitro micronucleus test in CHO-K1 cells. Study Nr. 190502/NL/PC. Mumbai, India.

Document Generated: 2023-12-13

Changes to legislation:

There are currently no known outstanding effects for the Commission Implementing Regulation (EU) 2020/1821.